Sonia García-Embid

Sonia García-Embid

Auto-generated profile, based on publicly available information

Sonia García-Embid

Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Chemical Engineering Journal
Verified
Journal Article
Open access
LML. De Matteis
L. De Matteis
DJD. Jary
D. Jary
ALA. Lucía
A. Lucía
SGS. García-Embid
S. García-Embid
ISInés Serrano
Inés Serrano
JFJ. M. de la Fuente
J. M. de la Fuente

23 May 2017 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
RMRafael Martín-Rapún
Rafael Martín-Rapún
LMLaura De Matteis
Laura De Matteis
AAAlfredo Ambrosone
Alfredo Ambrosone
SGSonia Garcia-Embid
Sonia Garcia-Embid
LGLucia Gutierrez
Lucia Gutierrez
Jesus M De La FuenteJesus M De La Fuente
Jesus M De La Fuente
Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive. Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed. Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration. Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies.

30 September 2016 in Marine Drugs
Verified
Journal Article
Open access
PDF file
LMLaura De Matteis
Laura De Matteis
MAMaria Alleva
Maria Alleva
ISInés Serrano
Inés Serrano
SGSonia García-Embid
Sonia García-Embid
GSGrazyna Stepien
Grazyna Stepien
Jesus M De La FuenteJesus M De La Fuente
Jesus M De La Fuente
The tunability of the properties of chitosan-based carriers opens new ways for the application of drugs with low water-stability or high adverse effects. In this work, the combination of a nanoemulsion with a chitosan hydrogel coating and the following poly (ethylene glycol) (PEG) grafting is proven to be a promising strategy to obtain a flexible and versatile nanocarrier with an improved stability. Thanks to chitosan amino groups, a new easy and reproducible method to obtain nanocapsule grafting with PEG has been developed in this work, allowing a very good control and tunability of the properties of nanocapsule surface. Two different PEG densities of coverage are studied and the nanocapsule systems obtained are characterized at all steps of the optimization in terms of diameter, Z potential and surface charge (amino group analysis). Results obtained are compatible with a conformation of PEG molecules laying adsorbed on nanoparticle surface after covalent linking through their amino terminal moiety. An improvement in nanocapsule stability in physiological medium is observed with the highest PEG coverage density obtained. Cytotoxicity tests also demonstrate that grafting with PEG is an effective strategy to modulate the cytotoxicity of developed nanocapsules. Such results indicate the suitability of chitosan as protective coating for future studies oriented toward drug delivery.

22 June 2018 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
AAAlvaro Artiga
Alvaro Artiga
SGSonia García-Embid
Sonia García-Embid
LMLaura De Matteis
Laura De Matteis
SMScott G Mitchell
Scott G Mitchell
Jesus M De La FuenteJesus M De La Fuente
Jesus M De La Fuente
Upon excitation of their localized surface plasmon resonance (LSPR) band, gold nanorods (AuNRs) show a characteristic light-to-heat transduction, a useful and versatile property for a range of biomedical applications such as photothermal therapy, drug delivery, optoacoustic imaging and biosensing, among others. Nanoparticle (NP)-mediated photothermal therapy (PTT) rests on the ability of nanomaterials to convert light energy into heat and can currently be considered as a promising method for selectively destroying tumor cells by (photo)-thermoablation. One inherent limitation to NP-mediated PTT is that the nanoparticles must arrive at the site of action to exert their function and this typically involves cellular internalization. Here we report the use of the Keggin-type polyoxometalate (POM) phosphotungstic acid (PTA) as an inorganic gelling agent for the encapsulation of plasmonic gold nanorods (AuNRs) inside a biocompatible and cell-adhesive chitosan hydrogel matrix. These functional sub-micrometric containers are non-cytotoxic and present the ability to adhere to the cytoplasmic membranes of cells avoiding any need for cellular internalization, rendering them as highly efficient thermoablating agents of eukaryotic cells in vitro.

1 August 2020 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
DGDaniel González
Daniel González
ABAna Isabel Becerro
Ana Isabel Becerro
ACAriadna Corral
Ariadna Corral
SGSonia García-Embid
Sonia García-Embid
Marcin BalcerzykMarcin Balcerzyk
Marcin Balcerzyk
MOManuel Ocaña
Manuel Ocaña

1 June 2018 in Applied Catalysis A: General
Verified
Journal Article
Open access
SGSonia García-Embid
Sonia García-Embid
FRFrancesca Di Renzo
Francesca Di Renzo
LMLaura De Matteis
Laura De Matteis
NSNicoletta Spreti
Nicoletta Spreti
Jesus M De La FuenteJesus M De La Fuente
Jesus M De La Fuente